Biologics research demands efficient data and sequence management to accelerate antibody discovery. At the computational bottleneck, AI offers transformative potential. Sapio’s ELaiN acts as an AI co-scientist that automates sequence analysis workflows. Running BLAST searches, performing multiple sequence alignments, and optimizing codons for diverse expression systems. By turning bioinformatics labor into rapid, iterative design cycles, ELaiN bridges antibody optimization with intelligent molecular biology automation.
 
Attendees will learn how this AI-driven approach accelerates therapeutic discovery while preserving scientific insight and experimental decision-making.
 

Speakers

Veronica DeFelice, Director of Biologic Products
Veronica’s career began in international discovery optimization and identification for biologics before evolving into comprehensive product development spanning discovery through commercialization. She has lent her expertise across diverse sectors, including intellectual property, patents and biotechnology investments, with a specialized focus on biologics, such as antibody discovery and cell and gene therapy, cultivating a rich, multifaceted perspective across industries. Her work centers on product development that bridges biologics and AI, where she artfully integrates technical innovation with strategic product vision. Drawing from her expansive background, she adeptly navigates intricate challenges while pioneering cross-disciplinary advancements across biologic scientific domains. Notably, her therapeutic expertise is exemplified through a patent from Technion University in Israel involving cardiac genetics patterns and a publication from the National Institute of Standards and Technology on 3D collagen fibers and scaffolding standards in cell-to-cell communications.
 
Rob Brown, Global VP, Head of Scientific Office
Rob Brown is Global VP, Head of Scientific Office Sapio Sciences. Prior to joining Sapio Sciences, he spent eight years at Dotmatics, where he held various positions, including Head of Global Presales and Head of Product Marketing & Product Management. Earlier in his career, he was responsible for product marketing teams for cheminformatics and bioinformatics at Accelrys, SciTegic, and MSI. Rob started his career as a postdoc and later research scientist in the Computer-Aided Molecular Design department at Abbott Laboratories (now AbbVie). He received his PhD in Cheminformatics from the University of Sheffield, UK.

Explore how federated knowledge graph architecture empowers Boehringer Ingelheim to scale data and AI. By enabling business domains to build and manage their own local graphs, the federation preserves autonomy while connecting distributed data into a unified enterprise view—reducing integration costs across use cases. A global semantic layer—what we call the Knowledge Foundation—resolves inconsistencies across domains, delivering AI-ready, context-rich data that supports scalable governance, discovery, and innovation in drug development and manufacturing. Finally, the discussion will reflect how this approach can be powered by platforms like metaphactory to unlock the value of data and accelerate decision-making through consumable knowledge and actionable insights.

Speaker: Maksim Kolchin, Technical Product Owner, Boehringer Ingelheim

Bio: Maksim Kolchin is Technical Product Owner at Boehringer Ingelheim, where he leads the development of an Enterprise Knowledge Graph Platform built on Semantic Web technologies, FAIR principles, and a federated data governance. The platform supports key areas such as drug discovery, clinical research, supply chain management, and etc. Maksim is passionate about tackling data integration challenges using both proven methods and emerging approaches like knowledge graphs, which he sees as essential to the next major leap in data interoperability.

AI is reshaping the way R&D gets done in life sciences, but scaling from pilot projects to enterprise-wide platforms still challenges many organizations. In this webinar, Shahram Ebadollahi, Nav.AI principal and former Chief Data and AI Officer at Novartis, shares a strategic blueprint for embedding AI into the fabric of scientific decision-making.
 
You’ll learn how forward-looking life sciences leaders are turning AI from a technical capability into an operating model for discovery, development, and compliance. Join us to: 

• Explore the structural, cultural, and governance shifts required for scalable AI in R&D
• Hear real-world examples of how AI is compressing time to insight and elevating scientific rigor
• Understand how leaders can align incentives, infrastructure, and oversight to make AI practical and transformative

Speakers

• Shahram Ebadollahi, Principal at Nav.AI
• Chris McSpiritt, VP of Life Sciences Strategy, Domino

GenAI shows promise in drug discovery, but cutting through the noise to understand where it’s truly making an impact can be difficult. This webinar will focus on how genAI is being applied in practical ways today, from designing novel molecules to predicting toxicity and extracting knowledge from complex datasets.

Asha Mahesh from Johnson & Johnson will share what it takes to make genAI useful and usable in discovery science. Join the webinar to:

• Learn which genAI use cases already deliver value across early discovery workflows and which remain aspirational
• Understand the foundational infrastructure, data strategy, and talent needed to support genAI at scale
• Get a realistic view of genAI’s limitations and what to watch for as the technology matures